Core Viewpoint - The company, Jinhe Biology, reported a strong performance in the first quarter of 2025, with significant growth in revenue and net profit, driven primarily by its veterinary chemical products, particularly the sales of its key product, Jinmeisu [4][12]. Revenue and Profit Growth - In Q1 2025, the company achieved an operating income of 625.15 million yuan, representing a year-on-year increase of 20.35% [4][12]. - The net profit attributable to shareholders was 51.12 million yuan, up 13.23% year-on-year [4][12]. - The gross profit margin stood at 35.78% [12]. Product Performance - Revenue from veterinary chemical products increased by 21.47% year-on-year, with Jinmeisu being a major contributor, especially in the U.S. market, which reached a historical high [2]. - The company plans to enhance its product offerings with the full production of a new factory in 2025, which will produce Jinmeisu, Tetracycline, and Strongly Mycin, thereby extending its product line [2]. Research and Development - R&D expenses grew by 27.03% in 2024, indicating a strong commitment to innovation [3]. - The company is focusing on expanding the application of Jinmeisu and has received approval for its use in additional target animals, including sheep [3]. Market Outlook - The global animal health industry is expected to continue growing, with the domestic market showing significant potential, as evidenced by a compound annual growth rate of 8.43% in the domestic veterinary drug market from 2019 to 2023 [5][11]. - The company is optimistic about the future, particularly in the veterinary biological products market and the pet market, which is also expanding [6][11]. Strategic Initiatives - The company is enhancing its collaboration with Shanghai Jiao Tong University to leverage synthetic biology for product development and innovation [8]. - Plans are in place to expand the pet health business, with a focus on both chemical and vaccine products [8]. Competitive Position - The company has established a strong presence in the overseas market, with 60-70% of its chemical products sold internationally, particularly in the U.S. [10]. - The company aims to strengthen its market position by enhancing customer satisfaction and expanding its product offerings in international markets [10].

证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 编号：2025-03 | 投资者关系活动 | ■其他 （投资者电话交流会） | | --- | --- | | 类别 | | | | 山西证券（邓周宇、刘浩然、魏赟、张智勇）；国盛证券（胡偌碧、 | | | 徐雨涵）；太平洋医药（周豫、乔露阳）；广发证券（罗佳荣、田鑫、 | | | 方程嫣）；中信证券（陈竹、王凯旋、韩世通、王郑洋）；中信建投 | | | 证券（贺菊颖、王云鹏、赖俊勇、袁清慧、刘若飞）；招商证券（侯 | | | 彪、许菲菲）；浙商医药（郭双喜、盖文化）；东吴医药（俞昊岚）； | | | 华源证券（陶宸冉）；兴业证券（乔波耀）；天风证券（刘一伯）； | | | 西部证券（邓琳茜）；信达证券（贺鑫）；华西证券（孙曼）；华泰 | | | 证券（李奕玮）；华福证券（王宣宇）；国信证券（彭思、高熹）； | | | 国泰海通（周航、吴晗）；申万医药（余玉君）；财通证券（邹一瑜）； | | | 中泰证券（祝嘉琦）；开源证券（阮帅）；平安证券（李峰）；中金 | | | 公司（吴婉桦）；中海基金（陈玮）；浙商证券（赵媛）；易 ...